10x Genomics Announces Collaboration with QIAGEN, N.V. for Co-Marketing and Co-Development of Sequencing and Single Cell Analysis Workflows and Informatics Solutions

10x Genomics Announces Collaboration with QIAGEN, N.V. for Co-Marketing and Co-Development of Sequencing and Single Cell Analysis Workflows and Informatics Solutions

February 09, 2016 04:00 PM Eastern Standard Time

PLEASANTON, Calif.--()--10x Genomics, Inc. today announced the establishment of a co-marketing and co-development collaboration with QIAGEN N.V. for the co-promotion and co-development of integrated workflow solutions for nucleic acid sequencing and single cell analysis.

"We welcome the opportunity to partner with QIAGEN, with their comprehensive offerings for genomic analysis, ranging from sample preparation technologies to bioinformatics solutions for the interpretation and analysis of genomic data," said Serge Saxonov, 10x's Chief Executive Officer. "Access to long-range sequence information is becoming the standard for obtaining the most comprehensive understanding of disease, and we expect this collaboration to allow our respective customers to gain valuable insights that have previously not been possible."

10x's microfluidics-based, Linked-Read sequencing products, built on the proprietary GemCode™ technology, provide researchers critical long-range sequence information from their existing sequencers. This includes phasing, structural variant analysis, de novo genome assembly, and remapping of difficult regions of the genome. In addition, 10x's recently introduced ChromiumTM product suite for single cell analysis allows for rapid and comprehensive analysis of dynamic transcription events from large numbers of individual cells.

The companies will each be co-marketing to their respective customers the 10x Chromium products along with QIAGEN's sample handling and preparation technologies, including the MagAttract HMW DNA kits, and informatics solutions. The Companies also plan to work together as part of a multi-phase collaboration to co-develop a comprehensive portfolio of products to improve sample preparation, sequencing, and single cell analysis to further enhance the information that their customers can derive from their research, including:

  • Optimizing QIAGEN's sample technologies for use with 10x Genomics GemCode and Chromium systems.
  • Supporting complete workflows to enable single-cell applications.
  • Investigating the implementation of 10x Genomics' GemCode technology with QIAGEN's proprietary GeneReader NGS System
  • Developing solutions for enabling the processing and analysis of 10X Genomics' "Linked-Reads" with QIAGEN's suite of leading bioinformatics solutions.

"QIAGEN's collaboration with 10X Genomics enables both companies to better serve NGS customers, helping them make groundbreaking advances in single-cell biology, bioinformatics and beyond," said Peer Schatz, CEO of QIAGEN. "10X Genomics is recognized for delivering critical long-range sequence information that greatly expands the quality of genome research. This partnership will further the potential of each of our product lines while providing significant new capabilities to NGS researchers."

About 10x Genomics, Inc.

10x Genomics meets the critical need for long range, structural and cellular information, with an innovative system that transforms the capability of existing short-read sequencers. Our Chromium™ System supports comprehensive genomics and high-throughput single cell transcriptomics. It enables researchers to discover previously inaccessible genomic information at unprecedented scale, including phased structural variants, phased single nucleotide variants, and dynamic gene expression of individual cells—while leveraging their existing sequencing systems and workflows.


for 10x Genomics, Inc.
Trisha Rule
[email protected]


Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.